The Global Ophthalmology Amniotic Membrane Market size is projected to reach USD billion by the end of 2029, and it is expected to grow at a high CAGR of 12% during the forecasting period 2022-2029. The amniotic membrane is the placenta's innermost layer, which comprises tissue and cells, which act as a wound healing for the re-growth of soft tissue. These amniotic membranes are used in eye surgery for healing and replacing the damaged eye tissues as the biologically active cells are present in the epithelial and stromal layer of the Amniotic membrane and release the growth factors and cytokines with anti-inflammatory, anti-immunogenic, and anti-fibrotic properties.
Download free sample @ https://www.datamintelligence.com/download-sample/ophthalmology-amniotic-membrane-market
The market growth is driven by the rising demand for the use of amniotic membrane as a biological bandage suitable for use on the eye surface due to its properties such as thin, lightweight, elastic, and transparent. These membranes are used to treat chemical burns, cornea ulcers, and disorders leading to ulcerations during surgical procedures involving the eye tissue excision.
The market is dominated by the presence of several ophthalmology amniotic membrane products. For instance, Dehydrated AmnioMatrix developed by Next Biosciences is a dry amniotic membrane with the epithelial layer of cells removed. It acts as a scaffold to which new cells can grow once placed on the wound. There is an increase in the research and development activities for developing ophthalmology amniotic membranes over the forecasted period.
The market is witnessing the filing of new patents related to the ophthalmology amniotic membrane. For instance, in May 2018, TissueTech Inc had been awarded patent 9,808,491 by the U.S. Patent Trademark Office. The patent covers the use of a gel composition comprising a morselized placental amniotic membrane and/or morselized umbilical cord as a method for treating an ocular wound or repairing damaged ocular tissue.
By Product Type
l Cryopreserved Amniotic Membrane
l Lyophilization Amniotic Membrane
By End User
l Ambulatory Surgical Centers (ASCs)
l Specialty Clinics
l Research and Academic Institutes
The global ophthalmology amniotic membrane market is highly competitive with the presence of several domestic and international players. FzioMed, Inc., Amniox Medical, Inc., Human Regenerative Technologies, LLC, Amnio Technology, LLC, Derma Sciences, and MiMedx Group, Inc are leading market players with a significant market share. Companies are following new product launches, product diversification, market expansion strategies for increasing their market penetration.
The market entry of new players intensifies the market competition. For instance, in July 2018, BioStem Life Sciences had entered the market with four placental-derived tissue products, including the multiple indications, including ophthalmology, orthopedic and advanced wound care markets. These four products are an amniotic tissue allograft flowable matrix, a chorion-free amniotic tissue allograft membrane, an amniotic tissue allograft membrane with a chorion layer, and an extracellular amniotic membrane allograft for ocular repair.
The companies enter into collaborations, mergers, strategic partnerships, purchasing agreements, and acquisitions to increase the demand for ophthalmology amniotic membrane and their expansion across the globe. For instance, in December 2017, AMNIOX Medical, Inc. (a TissueTech, Inc. company) had awarded a group purchasing agreement for Regenerative Skin Grafting Products with Premier. This agreement would allow the premier members to take advantage of special terms pre-negotiated by Premier for the full AMNIOX Medical portfolio of the wound and surgical solutions, known under the respective NEOX CLARINEX brand names.
Company Name: DataM Intelligence
Contact Person: Sai
Email: Send Email
Phone: +1 877 441 4866
Country: United States